Biosimilars

Evaluating Biosimilar Programs and Formularies

Integrating Biosimilars for HCPs, into Electronic Health Records, and in Clinical Pathways/Care Plans

Tracking Usage and Monitoring the Impact of Biosimilars

Protocols and Laws for Transitioning to Biosimilars

Transitioning to a Biosimilar Program

Increased Use of Biosimilars

Optimizing Transitions to Biosimilars

Optimizing Transitions to Biosimilars Continued

Assessing Patient Confidence With Biosimilars

Positioning Biosimilars in Clinical Practice

Key Structural and Operational Considerations for Biosimilar Adoption

The Role of Private Label Agreements in Enhancing Access to Biosimilars

Best Practices for Employers to Maximize Uptake of Biosimilars

The Economic Impact of Biosimilars

Biosimilars Are Getting a Foothold and Becoming Preferred, Says Dr James Chambers

Removing Need for Switching Studies Could Change Payer Perspectives of Biosimilars

Role of the Pharmacist in the Care Team to Contain Costs in Oncology

Private Label Biosimilars

How Health Care Institutions Can Leverage Biosimilars to Generate Savings

Biosimilar Whisky? This Expert Says It’s Doable, No Aging Required

Exploring 2022 Trends in Health and Hospital Drug Spending With Vizient

Biosimilars Are Being Approved but Not Reaching the Market

Progress in the US With Biosimilars, but Opportunities Remain

Podcast: This Week in Managed Care—States Gain Power to Alter ACA Offerings and Other Health News

Podcast: This Week in Managed Care—Verma on Health Data and Other Health News

The State of Biosimilars in the United States: The Center for Biosimilars® Peer Exchange

Podcast: This Week in Managed Care—New Voluntary Payment Model and Other Health News